Home › Funds › SHENKMAN CAPITAL MANAGEMENT INC › NUVB
SHENKMAN CAPITAL MANAGEMENT INC position in NUVB
NUVATION BIO INC · Health Care
SHENKMAN CAPITAL MANAGEMENT INC reported holding 4,000,000 shares of NUVB (NUVATION BIO INC) in its Q3 2026 13F filing — a position valued at US$4.2M, representing 0.85% of its reported portfolio and ranking #30 among its reported holdings. SHENKMAN CAPITAL MANAGEMENT INC has disclosed NUVB holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SHENKMAN CAPITAL MANAGEMENT INC's NUVB position evolved
SHENKMAN CAPITAL MANAGEMENT INC first disclosed a stake in NUVB in Q2 2026 at 3,000,000 shares (US$3.2M). The position peaked in Q3 2026 at 4,000,000 shares, worth US$4.2M. Across 2 filings, SHENKMAN CAPITAL MANAGEMENT INC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 4,000,000 shares valued at US$4.2M — an increase of 1,000,000 shares quarter over quarter.. Notable position changes include a 33% increase in Q3 2026 (shares fell 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 3.00M | $3.21M | New |
| Q3 2026 | 4.00M | $4.18M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NUVB and 13F data
NUVB (NUVATION BIO INC) is a Health Care company. 55 other funds we track also report a position in NUVB — the largest reported positions include Decheng Capital LLC (US$147.4M), Context Capital Management, LLC (US$53.1M), Omega Fund Management, LLC (US$45.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NUVB
- Decheng Capital LLC 25.95M sh · $147.42M · Q2 2026
- Context Capital Management, LLC 52.00M sh · $53.13M · Q3 2026
- Omega Fund Management, LLC 8.08M sh · $45.90M · Q2 2026
- Laurion Capital Management LP 7.70M sh · $43.10M · Q3 2026
- Polar Asset Management Partners Inc. 25.00M sh · $26.10M · Q2 2026
- Duquesne Family Office LLC 4.54M sh · $25.79M · Q2 2026
- Jones Hill Capital LP 4.49M sh · $25.13M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 3.30M sh · $18.74M · Q2 2026
- Redmile Group, LLC 3.03M sh · $17.22M · Q2 2026
- Knoll Capital Management, LLC 1.60M sh · $9.08M · Q2 2026
- ESSEX INVESTMENT MANAGEMENT CO LLC 1.34M sh · $7.53M · Q3 2026
- ABRAMS CAPITAL MANAGEMENT, L.P. 1.27M sh · $7.22M · Q2 2026
More on SHENKMAN CAPITAL MANAGEMENT INC
FAQ
How long has SHENKMAN CAPITAL MANAGEMENT INC held NUVB?
SHENKMAN CAPITAL MANAGEMENT INC has disclosed NUVB holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is SHENKMAN CAPITAL MANAGEMENT INC's current position in NUVB?
As of Q3 2026, SHENKMAN CAPITAL MANAGEMENT INC holds 4.00M shares of NUVB (NUVATION BIO INC), valued at $4.18M, representing 0.85% of its reported portfolio and ranking #30.
Has SHENKMAN CAPITAL MANAGEMENT INC been buying or selling NUVB?
In the latest 13F filing (Q3 2026), SHENKMAN CAPITAL MANAGEMENT INC increased its position in NUVB. The position peaked in Q3 2026 at 4.00M shares.
Which other funds hold NUVB?
Other major institutional holders of NUVB include Decheng Capital LLC, Context Capital Management, LLC, Omega Fund Management, LLC, among 55 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.